Menu Search
Equities

Biomerieux SA

BMXMF:PKL

Biomerieux SA

Actions
  • Price (USD)107.01
  • Today's Change-1.93 / -1.77%
  • Shares traded5.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 16:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

  • Revenue in EUR (TTM)3.81bn
  • Net income in EUR411.30m
  • Incorporated1967
  • Employees14.65k
  • Location
    Biomerieux SA376, chemin de l'OrmeCRAPONNE 69280FranceFRA
  • Phone+33 478872000
  • Fax+33 478872090
  • Websitehttps://www.biomerieux.fr/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BIM:PAR since
announced		Transaction
value
Lumed IncDeal completed05 Jan 202405 Jan 2024Deal completed0.25%9.63m
Data delayed at least 15 minutes, as of Nov 14 2024 12:27 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.